Circulating metabolites in progression to islet autoimmunity and type 1 diabetesShow others and affiliations
2019 (English)In: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 62, no 12, p. 2287-2297Article in journal (Refereed) Published
Abstract [en]
AIMS/HYPOTHESIS: Metabolic dysregulation may precede the onset of type 1 diabetes. However, these metabolic disturbances and their specific role in disease initiation remain poorly understood. In this study, we examined whether children who progress to type 1 diabetes have a circulatory polar metabolite profile distinct from that of children who later progress to islet autoimmunity but not type 1 diabetes and a matched control group.
METHODS: We analysed polar metabolites from 415 longitudinal plasma samples in a prospective cohort of children in three study groups: those who progressed to type 1 diabetes; those who seroconverted to one islet autoantibody but not to type 1 diabetes; and an antibody-negative control group. Metabolites were measured using two-dimensional GC high-speed time of flight MS.
RESULTS: In early infancy, progression to type 1 diabetes was associated with downregulated amino acids, sugar derivatives and fatty acids, including catabolites of microbial origin, compared with the control group. Methionine remained persistently upregulated in those progressing to type 1 diabetes compared with the control group and those who seroconverted to one islet autoantibody. The appearance of islet autoantibodies was associated with decreased glutamic and aspartic acids.
CONCLUSIONS/INTERPRETATION: Our findings suggest that children who progress to type 1 diabetes have a unique metabolic profile, which is, however, altered with the appearance of islet autoantibodies. Our findings may assist with early prediction of the disease.
Place, publisher, year, edition, pages
Springer, 2019. Vol. 62, no 12, p. 2287-2297
Keywords [en]
Beta cell autoimmunity, Metabolomics, Type 1 diabetes
National Category
Other Basic Medicine Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-75892DOI: 10.1007/s00125-019-04980-0ISI: 000500998600012PubMedID: 31444528Scopus ID: 2-s2.0-85070968581OAI: oai:DiVA.org:oru-75892DiVA, id: diva2:1345656
Note
Funding Agencies:
Juvenile Diabetes Research Foundation 4-1998-2744-1999-731 4-2001-4352-SRA-2014-159-Q-R
Special research funds for Oulu University Hospital in Finland
Special research funds for Tampere University Hospital in Finland
Special research funds for Turku University Hospital in Finland
Academy of Finland 250114
2019-08-262019-08-262019-12-19Bibliographically approved